In the light of these challenges, we hypothesized that targeting an upstream molecule in the TNF‐α/SREBP1 pathway could offer a potential therapeutic strategy for AATF mediated MASH‐HCC. The gene discussed is AATF; the disease is hepatocellular carcinoma.